A Comparative Study of Acute Toxicity of Drugs Used During Anticancer Therapy in Healthy and Tumor-Bearing Mice

Abstract

Abstract.A comparative study was performed, in healthy and Ehrlich ascites bearing mice, to ascertain if the acute toxicity of drugs can change in disease conditions. Adriamycin, cis-platinum, cyclophosphamide, 5-fluorouracil, vinblastine, morphine and cefoxitin were administered intravenously; prochlorperazine and acetylsalicylic acid were given orally, and dexamethasone and lonidamine were given by both routes. With the exception of morphine, the LDso's significantly decreased in tumor bearing animals. The highest potency ratios (about 4-6) were observed with prochlorperazine and cyclophosphamide and the lowest (1.3-1.4) with lonidamine given intravenously, adriamycin and acetylsalicylic acid. These results confirm that the toxic response may be strongly influenced by pathological states.

<p>Design of a Novel Theranostic Nanomedicine (III): Synthesis and Physicochemical Properties of Tumor-Targeting Cisplatin Conjugated to a Hydrophilic Polyphosphazene</p>

“…Also, increased BUN and creatinine values have been reported to be nephrotoxic. 3,23 The BUN and creatinine values of cisplatin-treated group (b) are much higher than that of the control group (a) whereas Polycisplatin-treated groups (c) and (d) show very low values similar to those of the control groups (a). In conclusion, Polycisplatin exhibited much lower nephrotoxicity compared with cisplatin.…”

“…In the case of cisplatin, all four mice survived at its lower dosage of 6.5 mg Pt/kg, but none of mice survived at the dose of 13 mg Pt/kg. According to the pharmaceutical paper, 23 the LD 50 value of cisplatin was estimated to be approximately 11 mg/kg equivalent to 7.12 mg Pt/kg. In case of Polycisplatin, no mortality was observed up to the dose of 2, 25, 100 mg/kg Polycisplatin.…”